Skip to main content
. 2018 Oct 26;21(Suppl Suppl 8):e25187. doi: 10.1002/jia2.25187

Abstract O214 – Table 1. Virological primary outcomes

Without M184V/I, N = 1489 (%) With M184 V/I, N = 137 (%)
Virological failure (VF) 17 (1.14) 4 (3)
a) 1st definition: 2x HIV‐RNA >50 copies/mL 10 (0.67) 1 (0.73)
b) 2nd definition: 1x HIV‐RNA >50 copies/mL + ABC/3TC/DTG stop 7 (0.47) 3 (2.1)
Treatment (ABC/3TC/DTG) discontinued for reasons other than VF 232 (15.58) 14 (10.22)
Virological blipsa (VB) had at least one blip during ABC/3TC/DTG 63 (4.2) 12 (8.8)
VB, median copies/mL (IQR) 79 (62 to 122) 72 (58 to 154)
VF incidence (per 1000 person‐years) 13.56 (8.43 to 21.83) 29.8 (11.17 to 79.39)

avirological blips: any viral load measurement >50 copies/mL, with viral load subsequently undetectable.